Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches
Authors:
- Chan-Chao ChangchienCCChan-Chao Changchien
Open Access
- 1 December 2007
- journal article
- review article
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 46 (4) , 379-388
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecologic Oncology, 2007
- Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trialAnnals of Oncology, 2006
- Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancerGynecologic Oncology, 2006
- Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-upGynecologic Oncology, 2006
- Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancerAnnals of Oncology, 2006
- Molecular mechanism of phenoxodiol‐induced apoptosis in ovarian carcinoma cellsCancer, 2005
- The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancerGynecologic Oncology, 2004
- Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot studyInternational Journal of Gynecological Cancer, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- CA125 and Placental Alkaline Phosphatase as Serum Tumor Markers in Epithelial Ovarian CarcinomaTumor Biology, 1992